肝病治疗仪治疗代偿期乙肝肝硬化患者的效果观察

Observation on the effect of hepatic therapy instrument on patients with liver cirrhosis in compensatory period

目的探讨肝病治疗仪联合多烯磷脂酰胆碱治疗代偿期乙肝肝硬化患者的效果。方法回顾性分析2020年6月—2023年8月湖北省麻城市人民医院收治的代偿期乙肝肝硬化患者90例,根据治疗方法不同分为观察组和参照组,参照组采用多烯磷脂酰胆碱治疗,观察组在参照组基础上联合肝病治疗仪治疗。比较两组临床疗效,并对治疗前后两组患者肝功能和肝纤维化指标水平进行比较,观察两组患者不良反应发生情况。结果观察组患者临床治疗总有效率(95.74%)高于参照组(79.07%)(χ^(2)=4.369,P=0.037)。治疗后,观察组患者ALT、AST和TBiL水平均明显低于参照组(P<0.05)。治疗后,观察组患者HA、PCⅢ和LN水平均明显低于参照组(P<0.05)。观察组患者不良反应总发生率(4.26%)低于参照组(18.60%)(χ^(2)=4.681,P=0.030)。结论代偿期乙肝肝硬化患者采用肝病治疗仪联合多烯磷脂酰胆碱治疗疗效显著,可明显提高患者肝功能,减轻肝纤维化程度,减少不良反应,值得临床进一步推广。

Objective To investigate the effect of liver therapy instrument combined with polyene phosphatidylcholine in the treatment of compensated hepatitis B cirrhosis.Methods A retrospective analysis was performed on 90 patients with compensated hepatitis B cirrhosis treated in our hospital from June 2020 to August 2023,who were divided into experimental group and reference group according to different treatment methods.The reference group was treated with polyene phosphatidylcholine,and the experimental group was treated with liver disease therapeutic apparatus combined.The clinical efficacy,liver function and liver fibrosis indexes before and after treatment,and the occurrence of adverse reactions were compared between the two groups.Results Compared with the reference group(79.07%),the total effective rate of experimental group(95.74%)was better(χ^(2)=4.369,P=0.037).Compared with the control group,ALT,AST and TBiL levels in experimental group were lower after treatment(P<0.05).Compared with the control group,the levels of HA,PCⅢand LN in experimental group were lower after treatment(P<0.05).Compared with the control group(18.60%),the incidence of adverse reactions in experimental group(4.26%)was lower(χ^(2)=4.681,P=0.030).Conclusion Hepatotherapy instrument combined with polyene phosphatidylcholine is effective in the treatment of compensated hepatitis B cirrhosis patients,which can significantly improve the liver function of patients,reduce the degree of liver fibrosis and reduce adverse 86 Modern Instruments&Medical Treatment,2024,Vol.30 No.3 reactions,and is worthy of further clinical promotion.